Oral tolerance prevents oral sensitization to dietary antigens (Ags), including proteins and haptens, and development of delayed-type hypersensitivity (DTH) responses. We showed here that plasmacytoid dendritic cells (pDCs) prevented oral T cell priming and were responsible for systemic tolerance to CD4 + and CD8 + T cell-mediated DTH responses induced by Ag feeding. Systemic depletion of pDCs prevented induction of tolerance by antigen feeding. Transfer of oral Ag-loaded liver pDCs to naive recipient mice induced Ag-specific suppression of CD4 + and CD8 + T cell responses to protein and hapten, respectively. Liver is a site of oral Ag presentation, and pDCs appeared to induce anergy or deletion of Ag-specific T cells in the liver relatively rapidly via a CD4 + T cell-independent mechanism. These data demonstrate that oral tolerance relies on Ag presentation by pDC to T cells and suggest that pDC could represent a key therapeutic target for intestinal and systemic inflammatory diseases.
INTRODUCTION
Oral tolerance is the physiologic mechanism by which the mucosal immune system prevents deleterious T cell-mediated delayed-type hypersensitivity (DTH) reactions to self and exogenous dietary and environmental antigens (Ag) including food proteins as well as small chemical molecules also known as haptens (i.e., drugs, dyes, conservatives, and flavor enhancers) (Dubois et al., 2005; Mowat, 2003) . Studies in animal models have documented that Ag feeding, prior to systemic immunization with the same Ag, prevents the development of specific T cell-mediated immunopathologies (Faria and Weiner, 2005) and CD4 + and CD8 + T cell-mediated DTH responses to proteins (Mowat, 2003) and haptens (Dubois et al., 2003) , respectively. Clinical studies have confirmed that systemic T cell tolerance can be induced by Ag feeding in humans and primarily affects T cell-mediated DTH responses but not B cell responses (Husby et al., 1994) . Along these lines, breakdown of oral tolerance to dietary Ag or to the gut flora can cause chronic intestinal inflammatory diseases, as illustrated by celiac disease and inflammatory bowel disease (IBD), respectively. Although CD4 + T cells have always been thought to contribute to intestinal inflammation, emerging data indicate that in both celiac disease and IBD, CD8 + T cells mediating DTH might initiate inflammation by exerting cytotoxicity against epithelial cells (Hue et al., 2004; Nancey et al., 2006) . Several mechanisms contribute to oral tolerance including anergy or deletion of antigen-specific T cells and activation of regulatory CD4 + T cells that encompass natural CD4 + CD25 + Foxp3 + and antigen-specific regulatory T (Treg) cells producing the cytokines TGF-b and/or IL-10 ( Dubois et al., 2005) . Although dendritic cells (DC) likely play a role in oral tolerance induction (Viney et al., 1998) , there is as yet no direct evidence of the implication of myeloid or other types of DC, and the sites of oral Ag presentation by DC remain elusive. Although orally administered Ag can be presented to T cells by DC in both Peyer's patches (PP) and mesenteric lymph nodes (MLN) (Kunkel et al., 2003) , oral tolerance requires MLN (Spahn et al., 2001; Worbs et al., 2006) but not PP (Spahn et al., 2001) . Oral Ag can be captured by DCs in the intestinal lamina propria (LP) and transported to MLN via the mesenteric lymph (Mowat, 2003) . The recent observation that myeloid DC of both MLN and LP can convert CD4 + T cells into Foxp3 + Treg in vitro (Coombes et al., 2007; Sun et al., 2007) , or induce IL-10-producing CD4 + Treg cells (Bilsborough et al., 2003) might explain their suspected role in oral tolerance (Viney et al., 1998) . However, oral tolerance also involves systemic diffusion of free Ag via blood. Indeed, a variable fraction of food protein entering blood vessels in the lamina propria reaches the liver via the portal vein and disseminates systemically, intact or in the form of polypeptides, in peripheral lymphoid organs (Swarbrick et al., 1979) . Direct evidence for a role of the liver in tolerance is provided by the observation that portocaval anastomosis, which prevents draining into the liver of Ags from the gut, abrogates oral tolerance to proteins or haptens (Cantor and Dumont, 1967; Yang et al., 1994) . Along these lines, it has been shown that T cell tolerance in the liver and in the spleen can occur within hours after Ag feeding (Gutgemann et al., 1998; Ju and Pohl, 2001; Li et al., 2004) , suggesting that Ag presentation by antigen-presenting cells (APCs) outside the gut-associated lymphoid tissues (GALT) can be involved in oral tolerance. Plasmacytoid DC (pDC) represent an unconventional type of APC that is typified by their ability to contribute to antiviral innate immunity by producing type I interferon (IFN) upon activation (Asselin-Paturel et al., 2001). They also participate in adaptive immune responses by directing either T helper 1 (Th1) cell or Th2 cell development (Boonstra et al., 2003) . However, pDC at the immature state have a poor capacity to support T cell proliferation (Asselin-Paturel et al., 2001 ) and can even suppress T cell responses (Bilsborough et al., 2003; Martin et al., 2002) . Indeed, pDC contribute to peripheral T cell tolerance including transplantation tolerance (Ochando et al., 2006) , tumor escape (Munn et al., 2004) , and mucosal tolerance in an animal model of asthma (De Heer et al., 2004) . However, whether and how pDC contribute to oral tolerance has not been previously studied.
The goal of this study was to identify the type and location of DC that could play an essential role in oral tolerance and could achieve efficient suppression of CD4 + and CD8 + T cell-mediated DTH responses. To monitor oral tolerance of CD8 + T cell-mediated DTH responses to a soluble Ag, we used a model of hapten-specific skin DTH, induced by CD8 + CTL independently of CD4 + T cell help (Desvignes et al., 2000) . In this model, covalent binding of the hapten to proteins generates hapten-modified self peptides, which are presented by MHC class I molecules and induce priming of IFNg-producing CD8 + CTL effectors mediating contact dermatitis (Dubois et al., 2003; Kehren et al., 1999) or colitis (Nancey et al., 2006) . We also analyzed the induction of oral tolerance in a classical model of DTH, mediated by specific CD4 + T cells, to a more conventional dietary protein, ovalbumine (OVA). We showed here that oral tolerance relies on pDCs, which suppress both CD4 + and CD8 + T cell-mediated DTH responses.
RESULTS

Oral Ag Is Rapidly Captured in the Liver and in Peripheral Lymphoid Organs
The localization and fate of oral Ag in normal mice was examined using 2.4-dinitrofluorobenzene (DNFB) as a model Ag, as its binding to self proteins allows in situ detection by staining with a DNP-specific mAb. Kinetic immunohistochemical analysis revealed that the hapten is detectable as early as 30 min after gavage in the gut epithelium, appears by 6 hr in the intestinal lamina propria, and disappears at 24 hr ( Figure 1A ). Because after local uptake the Ag was not identifiable by immunohistochemical analysis in lymphoid and nonlymphoid organs, we set up a functional ex vivo antigen presentation assay to determine the presence of Ag-presenting cells in different organs after intragastric administration of DNFB. To this aim, leukocytes were isolated from MLN, spleen, liver or different lymph nodes (LN) and used to stimulate the proliferation of CD8 + T cells from day 5 DNFBsensitized mice. CD8 + T cell proliferation was induced by leukocytes isolated from all organs of DNFB-fed mice except the spleen ( Figure 1B ). Leukocytes from MLN and inguinal or axillary LN induced specific CD8 + T cell proliferation at 2 and 24 hr after DNFB gavage. However, liver and hepatic LN cells were able to induce proliferation only when isolated at 2 hr but not at 24 hr, suggesting that the hapten rapidly disappeared from these two sites or that Ag-loaded APC from liver and hepatic LN become unable to stimulate CD8 + T cell proliferation. These data illustrate that orally administered hapten rapidly diffuses to the liver and hepatic LN and also reaches systemic LN including MLN.
Ag Delivery by Oral or Intraportal Route Prevents CD8 + T Cell-Mediated DTH We previously documented that oral administration of DNFB, prior to skin sensitization with the hapten, completely prevented the development of hapten-specific CD8 + T cells mediating contact hypersensitivity (CHS) (Desvignes et al., 2000; Dubois et al., 2003) . To determine whether systemic diffusion of dietary antigen via the hepatic portal venous system could contribute to 
CD8
+ T cell tolerance, we compared the CHS response in mice previously exposed to the Ag by gavage or by injection in the portal vein. Control mice injected with PBS in the portal vein developed an ear swelling response that peaked at 48 hr after DNFB challenge ( Figure 2A ) and correlated with the priming of hapten-specific interferon-g (IFN-g)-producing CD8 + T cells ( Figure 2B ). Oral gavage with DNFB or intraportal injection of DNBS (a soluble form of DNFB) were similarly efficient at inhibiting the DNFB-specific CHS response ( Figure 2A ) and prevented the differentiation of hapten-specific IFN-g-producing CD8
+ T cells ( Figure 2B ). Thus, oral gavage and immunization through the hepatic portal vein are equally efficient at inducing CD8 + T cell tolerance.
Plasmacytoid Dendritic Cells Are the Tolerogenic CD11c + DC of the Liver
To analyze whether hepatic DC after oral administration of Ag had tolerogenic functions, CD11c + cells were purified from the liver and tested for their capacity to induce or suppress hapten-specific T cell and CHS responses. CD11c + cells account for as much as 15%-20% of CD45 + liver leukocytes ( Figure 3A ) and exhibit an immature phenotype with low expression of MHC class II, CD80, and CD86, and a low allostimulatory potential (data not shown), confirming previous data (Lu et al., 2001; Watanabe et al., 2003) . Unlike in vitro-generated bone marrowderived DCs (BMDCs), liver CD11c + cells pulsed in vitro with DNBS were unable to induce a CHS response when injected subcutaneously (s.c.) into naive mice ( Figure 3B ). Moreover, unpulsed liver CD11c + DCs delivered at the site and time of DNFB skin sensitization completely prevented induction of the CHS response ( Figure 3C) Figure 3A) , both of which mostly contained DCs ( Figure S1A ). These three populations of CD11c + cells sorted on the basis of CD11b and NK1.1 expression ( Figure 3A ) were compared for their relative ability to inhibit the CHS response upon s.c. transfer at the time of skin sensitization. Figure 3D ) and prevented priming of hapten-specific IFN-g-producing CD8 + T cells in skin draining LN ( Figure 3E ). Interestingly, 60%-80% of CD11c Figure S1C ). We thus examined whether pDC accounted for the capacity of liver CD11c + DC to induce hapten-specific T cell tolerance. CD11c + NK1.1
À
CD11b
À leukocytes were sorted into 120G8 + (pDC) and 120G8 À cell subsets and injected s.c. into naive C57Bl/6 mice at the time of skin sensitization with DNFB. Adoptive transfer of FAC-sorted 120G8 À cells did not affect the frequency of hapten-specific IFN-gproducing CD8
+ T cells ( Figure 3E ), which are effector cells of CHS (Kehren et al., 1999) . In contrast, sorted 120G8 + pDC transfer decreased by 60% the frequency of hapten-specific IFN-gproducing CD8 + T cells ( Figure 3E ) and completely prevented the CHS response ( Figure 3F ). Thus, pDC were immunoregulatory and accounted for the tolerogenic property of liver DC. 
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Plasmacytoid DC Are Essential to Oral Tolerance pDC Are Required for Oral Tolerance of CD8 + and CD4 + T Cell-Mediated DTH Responses To directly address the role of pDC in oral tolerance, pDC were depleted in vivo using the RB6-8C5 anti-Gr1 mAb. Anti-Gr1 efficiently depleted $80% of liver pDC as assessed both by evaluating the remaining frequency of liver pDC by flow cytometry and by measuring the loss of ability of MAC-sorted CD11c + liver DC to produce IFN-a in response to virus stimulation, a functional property of pDC (Figures S2A and S2B) . Mice injected with the control rat mAb GL113 were tolerized by oral administration of the hapten, whereas oral tolerance was impaired in Gr1 mAb injected mice, as demonstrated by restoration of CHS ( Figure 4A ) and increased IFN-g production by CD8 + T cells ( Figure 4B ). Because the Gr1 mAb in addition to pDC also depleted neutrophils, eosinophils, and other Gr1 + cells, we tested whether tolerance could be reversed by injection of another mAb targeting pDC, i.e., the 120G8 mAb . Treatment with 120G8 efficiently depleted pDC from the liver ( Figure S2C ), MLN, and spleen (data not shown), as assessed by flow cytometry with anti-BST-2 or anti-SiglecH mAbs. Tolerance to DNFB could not be induced in 120G8-treated mice, as demonstrated by the similar intensity of the CHS ( Figure 4C ) and CD8 + T cell responses ( Figure 4D ) in both vehicle-fed and hapten-fed mice. Furthermore, systemic sensitization could be induced by a single DNFB gavage (without skin painting) in 120G8 mAb-treated mice, as evidenced by the development of a CHS response upon ear challenge 5 days later ( Figure 4E ). Thus, pDC are required for induction of CD8 + T cell tolerance by oral hapten delivery and their absence permits oral sensitization and development of a CHS response.
To confirm whether pDC were also required for oral tolerance to a more conventional dietary protein (ovalbumine, OVA), we used the classical model of DTH to OVA, mediated by specific CD4 + T cells. We showed that intragastric delivery of 20 mg of OVA 3 times on days À13, À10, and À7 (protocol depicted on Figure 5A ) nearly completely prevented the DTH response to OVA (80% of suppression of footpad swelling; Figure 5B ). In vivo depletion of pDC by 120G8 mAb treatment of OVA-fed mice, prevented suppression of footpad swelling and of IFN-g production by OVA-specific T cells, by roughly 50% ( Figures  5B and 5C ). Similar results were obtained in mice fed from day À14 to À7 with 20 mg/ml OVA in drinking water (data not shown). These data demonstrate that pDC also inhibit DTH responses induced by gavage with a protein Ag.
Comparison of the Tolerogenic Potential of pDC from Liver, MLN, and Spleen of Ag-Fed Mice We next examined the efficacy of tolerance induction by pDC from Ag-fed mice and asked whether it depended on their tissue origin. Graded numbers of MAC-sorted liver pDC, isolated from DNFB-or vehicle-fed mice ( Figure S3A ), were transferred into B6 recipient mice at the time of immunization with hapten-pulsed BM-DC and tested for their ability to inhibit CD8 + T cell-mediated CHS responses. pDC enriched from liver leukocytes of vehiclefed mice had a modest inhibitory effect only at the highest dose (10 5 ). In contrast, a dose-dependent suppression of the ear swelling response was achieved by transfer of pDC-enriched leukocytes from DNFB-fed mice, with significant inhibition with as few as 10 4 cells ( Figure 6A ). Importantly, transfer of 10 5 FAC-sorted pDC (which contained >97% pure pDC; Figures S3B and S3C) from liver or MLN cells of hapten-fed mice were similarly efficient to prevent in vivo priming of hapten-specific IFN-g-producing CHS effectors, whereas T cell priming was only moderately affected by transfer of splenic pDC either purified from vehicle-or DNFB-fed mice ( Figure 6B ). In addition, pDC purified from the liver, but not spleen, efficiently suppressed the proliferation of hapten-specific CD8 + T cells in vitro (Figure S4A) . Thus, pDC from the liver and MLN, but not spleen, of hapten-fed mice can induce T cell tolerance and suppression of DTH responses in vivo.
Suppression of DTH Responses by Liver pDC from Ag-Fed Mice Is Antigen Specific
To further analyze whether liver pDCs carrying oral Ag can control CD4 + or CD8 + T cell-mediated DTH reactions in an Ag-specific way, adoptive transfer experiments were performed. Transfer of liver pDCs purified by FACS from OVA-fed mice suppressed the DTH response induced by immunization with OVA-pulsed BMDCs ( Figure 6C ). In contrast, liver pDCs from DNFB-fed mice or from oxazolone (OXA)-fed animals did not modify at all the DTH response. Likewise, analysis in the model of CD8 + T cell mediated CHS response to DNFB, induced by immunization with DNBS-pulsed BMDCs, revealed that only pDCs from DNFB-fed mice could suppress skin inflammation, whereas pDCs from mice fed with the hapten OXA or the protein Ag OVA were inefficient ( Figure 6D) . Similarly, only pDC from DNFB-fed animals efficiently suppressed the proliferation of CD8 + T cells in vitro in an Agspecific way ( Figure S4B ). Together with the results described above ( Figure 5 ), these observations demonstrate that soon after feeding with a protein Ag or a hapten, liver pDC exhibit the capacity to present the oral Ag to T cells and to perform Ag-specific suppression of DTH responses in vivo.
Plasmacytoid DC Induce Anergy or Deletion of Ag-Specific T Cells in the Liver Shortly after Ag Feeding
The above results suggest that the liver constitutes a key organ where presentation of oral Ag by pDC might induce tolerance. To analyze the mechanism by which pDC in the liver induce tolerance, we analyzed the fate of Ag-specific CD8 + T cells after DNFB feeding. To circumvent the lack of tools to directly identify hapten-specific T cells, we developed a CHS model by transferring CD8 + T cells into T cell-deficient CD33-deficient mice. CD8 + T cells were purified from donor mice 1 or 6 days after vehicle or DNFB gavage, and adoptively transferred into Cd33 À/À recipient mice. Three weeks later, recipient mice were skin sensitized with DNFB and tested for their capacity to initiate a CHS response upon DNFB challenge. Recipients of CD8 + T cells isolated either from the liver or MLN of vehicle-fed control B6 donors were able to mount a CHS response after DNFB sensitization and challenge ( Figure 7A ). In contrast, adoptive transfer of CD8 + T cells from day 6 DNFB-fed donors hardly induced any ear swelling response in Cd33 À/À recipients and had a reduced capacity to differentiate into IFN-g-secreting effector T cells upon skin sensitization ( Figure 7B ). These results demonstrate that Ag feeding of B6 mice induces, in MLN and liver, a massive decrease of the number of hapten-specific T cells able to differentiate into DTH effector cells. Importantly, this loss of Ag-reactive T cells, revealed by an impaired capacity to differentiate into CHS effectors, was observed in MLN only at 6 days but not at 1 (Figure 7B ) or 3 days (data not shown) after DNFB feeding. In contrast, the impaired capacity to differentiate into CHS effectors occurred in the liver as early as day 1 and persisted up to day 6 after gavage. Thus, hapten feeding resulted in anergy or deletion of hapten-reactive CD8 + T cells that is rapid and long lasting in the liver but delayed in the MLN. Further, depletion of pDC prior to hapten feeding of donor mice completely prevented this anergy or deletion of hapten-reactive MLN CD8 + T cells and restored their ability to differentiate into CHS effectors when transferred into Cd33 À/À mice ( Figure 7C 
CHS response after adoptive transfer into Cd33
À/À -recipient mice ( Figure 7D ), indicating that the orally induced anergy or deletion of Ag-specific T cells does not involve CD4 + T cells. Altogether, these data show that anergy or deletion of T cells specific for the oral Ag occurs at early times in the liver and later in MLN, and is mediated by pDC independently of CD4 + T cells.
DISCUSSION
This study demonstrates that pDC presenting dietary Ags are responsible for induction of oral tolerance and immune suppression affecting both CD4 + and CD8 + T cell responses. Using models of oral tolerance to a classical dietary protein Ag (OVA) and to the allergenic hapten DNFB, we showed that suppression of systemic CD4 + or CD8 + T cell-mediated DTH responses requires pDC. Indeed, in vivo depletion of pDC using either the Gr1 (RB6.8C5) mAb (Asselin-Paturel et al., 2001) or the more selective BST-2 (120G8) mAb Blasius et al., 2006) abrogated oral tolerance and suppression of DTH responses in both models. A single intragastric hapten gavage in pDC-depleted naive mice resulted in oral T cell priming and development of a CHS response after skin hapten challenge. In addition, similarly to Ag feeding (Desvignes et al., 2000) , adoptive transfer of pDC from Ag-fed mice prevented T cell priming and induction of DTH responses in an Ag-specific way. The important role of pDCs in oral tolerance is in line with the previous observation that Flt3-L treatment, which by increasing the number of DC including pDC (Gilliet et al., 2002) , results in more efficient oral tolerance (Viney et al., 1998) .
Anergy or deletion of Ag-specific T cells and active suppression by regulatory T cells are the two major mechanisms involved in orally induced T cell tolerance (Dubois et al., 2005; Mowat, 2003) . We provide in vivo evidence that the main mechanism by which pDCs contribute to oral tolerance is by inducing anergy and/or deletion of nearly 70%-80% of Ag-specific T cells. Indeed, Ag feeding impaired the capacity of Ag-reactive T cells from liver and MLN of B6 donor mice to differentiate into DTH effectors upon adoptive transfer into T cell-deficient Cd33 À/À mice, and this effect was completely prevented by pDC depletion of donor mice. Interestingly, pDC-mediated functional inactivation of Ag-specific T cells did not require CD4 + T cells indicating that the mechanism by which pDCs reduces the size of the circulating pool of Ag-specific T cells is independent of their capacity to trigger CD4 + Treg cell differentiation. It can be postulated that pDCs, which harbor low amounts of MHC peptide complexes and costimulatory molecules (Asselin-Paturel et al., 2001) , make short or weak interactions with naive T cells. Similarly to conventional immature DC (Gett et al., 2003) , pDCs may thus induce abortive proliferation and/or desensitization of Ag-specific T cells that fail to differentiate into CD4 + or CD8 + effector or memory T cells and die by neglect. The newly recognized cytotoxic potential of pDCs and the production of molecules favoring T cell apoptosis, like IDO (Sharma et al., 2007) and TNF-a (Kingham et al., 2007) , could explain their suppressive function.
Due to its unique vascular supply, the liver receives via the portal vein a majority of soluble Ag from the gut lamina propria and has long been recognized as an immune-privileged organ that contributes to oral tolerance. Previous studies reported that creating a portocaval shunt to bypass the liver and prevent Ag transport from the gut to the liver via the portal vein, abrogates oral tolerance in response to either protein or hapten (Cantor and Dumont, 1967; Yang et al., 1994) , Ag known to induce CD4 + and CD8 + T cell-mediated DTH. More recent studies using orthotopic (B and C) Tolerance induction was analyzed by measurement of the DTH reaction 24 hr after challenge (mean ear swelling ± SD of five mice per group) and (C) OVA-specific T cell IFN-g production by spleen cells collected 48 hr after challenge and restimulated in vitro with 1 mg/ml OVA (mean UI/ml ± of triplicate wells). *** p = 0.001; ** p = 0.0018.
liver transplants from OVA-fed donors documented that the liver within hours after gavage is sufficient to transfer oral tolerance and prevent systemic DTH to OVA and that this effect could be reproduced by transfer of liver nonparenchymal cells (Li et al., 2004) . The possible importance of the liver as an inductive site of oral tolerance is further supported by our present data showing that the liver is highly enriched with pDC endowed with a tolerogenic potential, and is a site where pDCs induce anergy or deletion of Ag-specific T cells early after Ag feeding. pDCs, which account for up to 30% of liver CD11c + cells, represented the only DC subset of the liver able to suppress a CHS response by preventing in vivo priming of hapten-specific IFN-g-producing CD8 + effectors, when transferred at the time and site of hapten sensitization. Although oral hapten rapidly distributes from the gut lamina propria to the liver as well as to the GALT and systemic lymphoid organs, anergy or deletion of Ag-reactive T cells is detected by day 1 in the liver and only several days later in MLN, suggesting that the very early CD4 + T cell-independent phase of oral tolerance to haptens is initiated by the Ag diffusion through the hematic route rather than by Ag transport into the draining MLN. Furthermore, we document that T cell tolerance and ability to prevent CHS to DNFB is achieved equally well by oral and intraportal antigen delivery. pDCs might also exert their suppressive function in lymphoid organs during induction of oral tolerance. In this respect, pDCs harvested from MLN and liver of hapten-fed mice have the same efficacy to prevent hapten-specific CD8 + T cell priming, if transferred in similar numbers into recipient mice, indicating that, on a per cell basis, they share similar tolerogenic properties, although their in vivo tolerogenic potential could be conditioned in vivo by the local microenvironment (Bilsborough et al., 2003; Contractor et al., 2007) . The fact that pDC from spleen of Ag-fed mice were weakly suppressive upon in vivo transfer may relate to the limited amount of oral Ag reaching the spleen, inasmuch as they could suppress hapten-specific CD8 + T cells when pulsed in vitro with the Ag. Although our study highlights an unanticipated and essential role of pDCs in the rapid and efficient anergy or deletion of T cells specific to orally administrated Ag, we demonstrated earlier that oral tolerance to DNFB also critically depends on CD4 + regulatory T cells ( 18 hr earlier with either DNFB, OXA, or OVA. Five days after immunization, recipients of DNBS-pulsed BM-DC were ear challenged with DNFB, and the ear swelling response was determined after 48 hr (C) *** p = 0.0002. All mice that received OVA-pulsed BM-DC were challenged with aggregated OVA in the footpad 7 days after immunization, and the DTH response, as measured by footpad swelling, was determined after 48 hr (D) * p = 0.03. These data are representative of two independent experiments.
escaped anergy or deletion or may have recently emigrated from the thymus. Recent studies using elegant approaches of surgical ablation of MLN as well as leukocyte sequestration in secondary lymphoid organs, provided convincing evidence that MLN were essential for oral tolerance in a model of CD4 + T cell-mediated DTH response (Worbs et al., 2006) . Thus, it is tempting to speculate that MLN and liver may play complementary roles with a division of labor with different temporal requirements to achieve efficient oral tolerance. On the one hand, the liver due to its 
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Plasmacytoid DC Are Essential to Oral Tolerance anatomical characteristics, and the constant blood flow is the first site exposed to large quantities of oral Ag in soluble form and pDC enriched in this organ cause rapid and efficient deletion of oral Ag-specific T cells (this study) constantly trafficking from the blood. This is consistent with the observation that the liver constitutes a privileged site for apoptosis of both CD8 + T cells (Crispe, 2003) and CD4 + T cells (Watanabe et al., 2003) . On the other hand, MLN which collects via lymph intestinal Ags loaded onto myeloid DC emigrating from lamina propria might constitute the preferential site of activation/differentiation of regulatory T cells specific for dietary Ag (Thorstenson and Khoruts, 2001; Zhang et al., 2001) . In this respect, myeloid CD103 + DC from the MLN have the potential to drive the differentiation of functional Foxp3 + Treg in vitro in the presence of retinoic acid and TGF-b (Coombes et al., 2007) , although the role of CD103 + DC in oral tolerance remains to be formally demonstrated. Our data clearly demonstrate that pDC perform efficient CD4 + and CD8 + T cell tolerance to orally administered haptens and proteins. The notion that pDCs may control the emergence of food allergy, drug-induced allergic DTH reactions, as well as intestinal inflammatory diseases, and also favor transplantation tolerance opens up new avenues for the development of therapeutic approaches targeting pDC.
EXPERIMENTAL PROCEDURES
Mice Female C57BL/6 mice (2-4 months old) were purchased from Charles River Laboratories (L'Arbresle, France). MHC-class II (H2-Ab À/À )-deficient mice were kindly provided by D.Mathis and C. Benoist, and CD33 À/À mice were obtained from M. Malissen. These mice were bred as homozygotes at the institute's animal facility (Plateau de Biologie Expé rimentale de la Souris, PBES, Ecole Normale Supé rieure de Lyon) under specific pathogen-free conditions. All experiments have been approved by the ''Comité regional d'é thique pour l'expé rimentation animale'' (CREEA) and were performed according to institutional guidelines.
Contact Hypersensitivity (CHS) to DNFB Mice were sensitized epicutaneously on abdominal skin with 0.5% DNFB (Sigma, St. Quentin Fallavier, France) diluted in acetone-olive oil (4:1, v/v) and ear-challenged 5 days later with 0.15% DNFB. CHS was determined by the mouse ear swelling test as previously described (Dubois et al., 2003) . Ear swelling in unsensitized but ear challenged mice was usually <20 mm. In some experiments (tolerance induced by the portal vein), mice were sensitized on the dorsal skin with 0.2% of DNFB. CHS was also induced by s.c. injection of BM-DC (10 5 cells) pulsed with 1.6 mM of DNBS.
Delayed Type Hypersensitivity (DTH) to OVA Mice were immunized subcutaneously with 50 mg OVA (Seikagaku corporation, Tokyo, Japan) in 50 ml PBS/CFA emulsion, or 10 5 OVA-pulsed BM-DC, and were challenged 7 days later by s.c. injection of 250 mg aggregated OVA in 30 ml of PBS in the left hind footpad. The right footpad received PBS as control. OVA-specific DTH was determined by footpad swelling at various times after challenge, as described (Krasteva et al., 1998) .
Tolerance Induction by Intragastric or Intraportal Antigen Delivery
Oral tolerance to DNFB was induced by intragastric administration of 0.1% DNFB (300 ml) in acetone/olive oil (1/10, v/v) 7 days before skin sensitization with DNFB, as described (Desvignes et al., 2000) . For induction of tolerance to OVA, mice were fed three times 20 mg of OVA (grade II, Sigma-Aldrich) in 200 ml PBS by gavage on days À13, À10, and À7 before OVA/CFA immunization. Tolerance via the portal route was induced by injection of 125 mg/kg of DNBS (Sigma) in 100 ml of PBS into the portal vein of mice under isoflurane anesthesia. For depletion of pDC, mice received multiple injections (200 ml) of either of anti-Gr1 antibody (clone RB6-8C5) as 1/5 dilution of ascitic fluid in PBS, or 0.5 mg of purified rat IgG anti-BST-2 mAb (clone 120G8) (AsselinPaturel et al., 2003) .
Isolation of Liver, Spleen, and MLN Leucocytes Leucocytes were isolated from liver, MLN, and spleen by enzymatic digestion at 37 C for 30 min using collagenase type IA (1 mg/ml) and DNase I (0.1 mg/ml) (each from Sigma, St Quentin Fallavier, France). Liver (Lian et al., 2003) leukocytes were separated from contaminating hepatocytes by centrifugation over a 40%-80% Percoll gradient (Percoll, density 1,130, Amersham Biosciences) (Lian et al., 2003) .
Flow Cytometry Analysis
Phenotypic studies were conducted by direct immunofluorescence staining using the following Ab panel from Becton Dickinson (Le Pont de Claix, France): biotinylated or phycoerythrin (PE)-conjugated hamster anti-mouse CD11c (clone HL3), FITC, or PE-Cy5.5-conjugated rat anti-mouse CD11b (clone M1/70), PE-conjugated rat anti-mouse CD8a (clone 53-6.7), PE-conjugated mouse anti mouse NK1.1 (clone PK136). We also used Alexa488-conjugated rat anti mouse pDCs (clone 120G8) Figure 3E ), were obtained with a purity >97%. Alternatively, pDC were enriched from the liver, MLN, or spleen by MACS using mPDCA1-coated microbeads and MS columns (Miltenyi Biotec). This yielded 70%-80% pure pDC expressing CD11c and BST-2 ( Figure S3A ). For certain experiments, >97% pure CD11c int BST-2 + pDC were obtained by FACS ( Figure S3B ).
Ag-Specific T Cell Responses
The presence of hapten-specific T cells was determined by proliferation assay, IFN-g ELISA, and IFN-g ELISPOT after in vitro restimulation of either MACsorted CD8 + T cells or total LN cells with hapten-pulsed spleen cells or BM-DC as described (Dubois et al., 2003; Le Borgne et al., 2006) . For ex vivo antigen presentation assay, 10 5 leukocytes isolated from either DNFB or vehicle-fed mice were used as APC and cocultured with hapten-specific CD8 + T cells. Hapten-specific T cell proliferation was determined on day 3 of culture by 3 H-thymidine incorporation (1 mCi/well) during the last 8 hr of culture. OVA-specific T cell responses were determined by measuring IFN-g production by spleen cells stimulated for 48 hr in vitro with 1 mg/ml OVA.
Statistical Analysis
Statistics were performed using the Student's t test. P values <0.05 were considered to be statistically significant.
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